abstract: BACKGROUND: Accurate data about childhood @entity1 ( @entity1 ) in low- and middle-income countries are lacking. Our study is designed to assess survival of childhood @entity1 at King Hussein Cancer Center (KHCC) using modified St. Jude @entity0 's Research Hospital protocols. @entity0 AND METHODS: We reviewed the medical records of @entity0 1-18 years of age who were diagnosed with @entity1 and treated at KHCC from January 2003 through December 2009. Disease characteristics and outcome were analyzed. RESULTS: Over a 7-year period, 300 @entity0 with @entity1 were treated. One hundred and seventy-three (57.7%) were males and 127 (42.3%) were females. The median age at diagnosis was 5 years. One hundred and fifty-seven (52.3%) @entity0 were classified as low-risk, 118 (39.3%) were standard-risk and 25 (8.3%) were high-risk. Two hundred and sixty-two (88.5%) @entity0 had pre-B cell phenotype and 34 (11.5%) had T-cell phenotype. Two hundred and seventy-three (91.3%) @entity0 were classified as having CNS I disease, 24 (8%) had CNS II, and 2 (0.67%) had CNS III. @entity2 included: t(12;21) in 30 (12%) @entity0 and t(9;22) in 18 (7.4%). Four (1.3%) @entity0 died in induction, 6 (2%) died in first remission and 27 (9%) relapsed. After a median follow-up of 34.5 months (range 0.32-84.5), the estimated 5-year event free survival and overall survival were 80% and 89%, respectively. CONCLUSION: Treatment protocols developed by major cooperative groups and institutions to treat childhood @entity1 was successfully adapted and suggest that such an approach may be useful in other low- and middle-income countries.

title: Outcome of childhood XXXX in Jordan.

answer: @entity1


abstract: Seven hundred @entity0 at a community hospital underwent gastric bypass for morbid @entity1 . @entity2 developed in 14.9 percent. The incidence of major complications was particularly low. Both @entity3 and the percentage of excess weight lost in the postoperative period were very satisfactory. The criteria for selecting @entity0 for gastric bypass are presented and preoperative evaluation is reviewed. Major technical points in the operation are stressed. Roux-Y reconstruction of gastrointestinal continuity is the preferred technique in our hands. This report reemphasizes the safety and efficacy of gastric bypass as a treatment for morbid @entity1 . When careful @entity0 selection, preoperative evaluation and operative techniques are combined. excellent results can be expected in the community hospital.

title: Gastric bypass for XXXX . Results of a community hospital series.

answer: @entity1


abstract: The introduction of @entity5 ( @entity5 ) analogs and their antagonists is revolutionizing the treatment of @entity3 . In this study, @entity6 ( @entity6 ) microspheres containing a highly potent @entity5 antagonist ( @entity8 ) of interest in the indication of @entity3 were evaluated on release mechanisms in vitro and biological performance in vivo. @entity8 microspheres were prepared by the water/oil/water double emulsion method and the solid/oil/oil method. The results showed that the mechanism of @entity8 releasing from @entity6 14,000 microspheres was the cooperation of drug diffusion and polymer degradation. This clarified the relationship between the microsphere characterization and hormone level in vivo. The larger microspheres (33  m) could inhibit the @entity2 level to castration for a longer time (35 days) than the smaller microspheres (15  m, 14 days). The formulation containing the hydrophilic additive ( @entity4 ) could suppress the @entity2 level to castration for a longer time (> 35 days) than the formulation without @entity4 (14 days). The appearance of testis, @entity7 , and prostates changed after treatment. The weights of sexual organs decreased significantly. The in-vivo release of the @entity8 @entity6 14,000 microspheres curve showed that in-vivo release started immediately after day 1 (22.7%) and was rapid during the first 5 days (40.2% release). The @entity8 microspheres could be a promising drug delivery system candidate to treat sex hormone-dependent @entity0 and other @entity1 .

title: In-vitro/in-vivo studies of the biodegradable XXXX microspheres of a novel @entity5 antagonist for @entity3 treatment.

answer: @entity6


abstract: The introduction of @entity5 ( @entity5 ) analogs and their antagonists is revolutionizing the treatment of @entity3 . In this study, @entity6 ( @entity6 ) microspheres containing a highly potent @entity5 antagonist ( @entity8 ) of interest in the indication of @entity3 were evaluated on release mechanisms in vitro and biological performance in vivo. @entity8 microspheres were prepared by the water/oil/water double emulsion method and the solid/oil/oil method. The results showed that the mechanism of @entity8 releasing from @entity6 14,000 microspheres was the cooperation of drug diffusion and polymer degradation. This clarified the relationship between the microsphere characterization and hormone level in vivo. The larger microspheres (33  m) could inhibit the @entity2 level to castration for a longer time (35 days) than the smaller microspheres (15  m, 14 days). The formulation containing the hydrophilic additive ( @entity4 ) could suppress the @entity2 level to castration for a longer time (> 35 days) than the formulation without @entity4 (14 days). The appearance of testis, @entity7 , and prostates changed after treatment. The weights of sexual organs decreased significantly. The in-vivo release of the @entity8 @entity6 14,000 microspheres curve showed that in-vivo release started immediately after day 1 (22.7%) and was rapid during the first 5 days (40.2% release). The @entity8 microspheres could be a promising drug delivery system candidate to treat sex hormone-dependent @entity0 and other @entity1 .

title: In-vitro/in-vivo studies of the biodegradable @entity6 microspheres of a novel XXXX antagonist for @entity3 treatment.

answer: @entity5


abstract: The introduction of @entity5 ( @entity5 ) analogs and their antagonists is revolutionizing the treatment of @entity3 . In this study, @entity6 ( @entity6 ) microspheres containing a highly potent @entity5 antagonist ( @entity8 ) of interest in the indication of @entity3 were evaluated on release mechanisms in vitro and biological performance in vivo. @entity8 microspheres were prepared by the water/oil/water double emulsion method and the solid/oil/oil method. The results showed that the mechanism of @entity8 releasing from @entity6 14,000 microspheres was the cooperation of drug diffusion and polymer degradation. This clarified the relationship between the microsphere characterization and hormone level in vivo. The larger microspheres (33  m) could inhibit the @entity2 level to castration for a longer time (35 days) than the smaller microspheres (15  m, 14 days). The formulation containing the hydrophilic additive ( @entity4 ) could suppress the @entity2 level to castration for a longer time (> 35 days) than the formulation without @entity4 (14 days). The appearance of testis, @entity7 , and prostates changed after treatment. The weights of sexual organs decreased significantly. The in-vivo release of the @entity8 @entity6 14,000 microspheres curve showed that in-vivo release started immediately after day 1 (22.7%) and was rapid during the first 5 days (40.2% release). The @entity8 microspheres could be a promising drug delivery system candidate to treat sex hormone-dependent @entity0 and other @entity1 .

title: In-vitro/in-vivo studies of the biodegradable @entity6 microspheres of a novel @entity5 antagonist for XXXX treatment.

answer: @entity3


abstract: OBJECTIVE: To evaluate effects of lung recruitment maneuvers on @entity1 , systemic circulation, and lung mechanics in @entity0 with @entity2 . DESIGN: Prospective observational clinical study. SETTING. General intensive care unit of university hospital. @entity0 AND @entity0 : Fourteen @entity0 with @entity2 (ten in the main study group and four in a validation group). INTERVENTIONS. Three 2-min-long recruitment maneuvers (RM) with transient increases in mean airway pressure to 35 cm @entity3 (RM1 and RM2) and 44 cm @entity3 (RM3). MEASUREMENTS AND RESULTS: Measurements of systemic hemodynamics, @entity1 (laser Doppler flowmetry), and lung mechanics were performed immediately before, at the end of, and 3 min after each RM. Cardiac index decreased during all RMs while mean arterial pressure decreased only during RM3. Gastric mucosal perfusion was not significantly changed during any of the RMs. When comparing values obtained before the first RM with values after the third RM there was a significant decrease in cardiac index ( P=0.043) and a non-significant ( P=0.051) decrease in @entity1 . There were no significant changes in systemic oxygenation or lung mechanics after three RMs, even though four @entity0 showed marked transient increases in systemic oxygenation during RMs. CONCLUSIONS: In this study of ten @entity0 there were no significant changes in @entity1 during lung recruitment maneuvers. There was, however, a trend towards gradual decreases in @entity1 .

title: Do lung recruitment maneuvers decrease XXXX ?

answer: @entity1


abstract: PURPOSE: To compare repeat penetrating keratoplasty (PK) with Boston type I keratoprosthesis (KPro) implantation for full-thickness donor @entity1 . DESIGN: Previous donor graft failure is a common indication for both PK and KPro implantation. Selection of the surgical procedure is entirely dependent on the surgeon because there are no studies available for guidance. Therefore, a systematic review was undertaken to examine vision, device retention, graft clarity, and @entity0 and @entity2 outcomes after repeat PK versus KPro implantation. METHODS: Articles with data regarding repeat PK published between 1990 and 2014 were identified in PubMed, EMBASE, the Latin American and Caribbean Health Sciences Literature Database, and the Cochrane Central Register of Controlled Trials and were reviewed. Results were compared with a retrospective review of consecutive, nonrandomized, longitudinal case series of KPro implantations performed at 5 tertiary care centers in the United States. Visual acuity at 2 years was the primary outcome measure. The proportion of clear grafts in the repeat PK group, device retention in the KPro group, and the development of @entity0 and @entity2 were secondary outcome measures. RESULTS: The search strategy identified 17 128 articles in the PK analysis. After screening, 26 studies (21 case series and 5 cohort studies) were included in the review. Pooled analysis of the 26 unique studies demonstrated a 42% (95% confidence interval [CI], 30%-56%) likelihood of maintaining 20/200 or better at 2 years after repeat PK, compared with an 80% (95% CI, 68%-88%) probability with KPro implantation. The probability of maintaining a clear graft at 5 years was 47% (95% CI, 40%-54%) after repeat PK, whereas the probability of retention of the KPro at 5 years was 75% (95% CI, 64%-84%). The rate of progression of @entity3 at 3 years was 25% (95% CI, 10%-44%) after repeat PK and 30% in the KPro cohort. CONCLUSIONS: These results demonstrate favorable outcomes of KPro surgery for donor @entity1 with a greater likelihood of maintaining visual improvement without higher risk of @entity0 compared with repeat donor PK.

title: Boston Type 1 Keratoprosthesis versus Repeat Donor Keratoplasty for XXXX : A Systematic Review and Meta-Analysis.

answer: @entity1


abstract: INTRODUCTION: @entity13 ( @entity13 ) is a systemic @entity2 . The most well-known posterior segment presentation is @entity9 with a macular star. In this study, we present a case series emphasising the heterogeneity of the disease and the various posterior segment manifestations. MATERIALS AND METHODS: A retrospective case series of consecutive @entity0 presenting with posterior segment @entity13 , over a 5-year period (2010 to 2015), at two ophthalmological centres in Midi-Pyr  n  es. RESULTS: Twelve @entity0 (17 eyes) were included, of whom 11 (92%) presented with rapidly decreasing visual acuity, with 6 of these (50%) extremely abrupt. @entity13 was bilateral in 5 (42% of all @entity0 ). Posterior manifestations were: 12 instances of @entity1 (100%), 8 of focal @entity11 (67%) and only 6 of the classic @entity6 with macular star (25% at first examination, but 50% later). Other @entity4 developed in three @entity0 ; one developed acute @entity12 , one a @entity5 and one a branch retinal @entity3 , all secondary to occlusive @entity7 adjacent to focal @entity11 . CONCLUSION: Classical @entity9 with macular star is not the only clinical presentation of @entity13 . Practitioners should screen for @entity10 in all @entity0 with @entity8 or focal @entity11 .

title: Posterior segment involvement in XXXX : A case series.

answer: @entity13


abstract: The aim of this study was to evaluate computed tomography (CT) in the assessment of @entity2 with particular reference to their longitudinal extent. Twenty-nine @entity0 were examined by CT, 21 of whom came to surgery. Sixteen of these 21 @entity0 were also examined by ultrasound. At CT the relation of the @entity1 to the renal arteries proximally and the bifurcation distally was noted, along with the definition of the aortic outline. At subsequent surgery the longitudinal relations of the @entity1 and evidence of localized stretching of or leakage from the sac were assessed by an observer without knowledge of the CT scan report. Correct extent of the @entity1 in relation to the renal arteries was predicted by CT in 20 out of 21 @entity0 who underwent surgery. CT assessment with respect to the bifurcation was correct in 16. The CT findings proved correct in one @entity0 with localized stretching of one part of the @entity1 and in one @entity0 where leakage was occurring. CT scanning was found to be superior to ultrasound in our preoperative assessment of the superior extent of @entity2 . CT is considered to be the investigation of first choice when evaluation an @entity2 .

title: Computed tomography (CT) of XXXX : determination of longitudinal extent.

answer: @entity2


abstract: UNASSIGNED: @entity3 -associated @entity4 ( @entity4 ) reductions are linked to improved @entity0 survival. We evaluated @entity4 at six time points to determine the timing of greatest reduction following @entity3 initiation. We sampled 40 Kaiser Permanente Northwest @entity2 receptor (ER)-positive @entity0 @entity1 from a prior study of @entity4 change, according to @entity3 use duration and age at diagnosis: <4 years @entity3 and  <=50 years (N = 6) or >50 years (N = 10) old; >= 4 years @entity3 and  <=50 years (N = 13) or >50 years (N = 11) old. A single reader evaluated percent @entity4 in the contralateral breast on baseline (pre-diagnosis) and five approximately yearly post-diagnostic (T1 to T5) mammograms. Mean @entity4 change was calculated. Interactions with age ( <=50 and >50 years), @entity3 duration (<4 and >= 4 years), and baseline @entity4 (tertiles) were tested in linear regression models. Overall, the largest @entity4 decline occurred by T1 (mean 4.5%) with little additional decline by T5. Declines differed by tertile of baseline @entity4 (P interaction < 0.01). In the highest tertile, the largest reduction occurred by T1 (mean 14.9%), with an additional reduction of 3.6% by T5. Changes were smaller in the middle and lowest baseline @entity4 tertiles, with cumulative reductions of 3.0% and 0.4% from baseline to T5, respectively. There were no differences by age (P interaction = 0.36) or @entity3 duration (P interaction = 0.42). Among ER-positive @entity1 treated with @entity3 and surviving >= 5 years, most of the @entity4 reduction occurred within approximately 12 months of @entity3 initiation, suggesting that @entity4 measurement at a single time point following @entity3 initiation can identify @entity1 with substantial density declines. Cancer Epidemiol Biomarkers Prev; 25(1); 1-5.   2015 AACR.

title: Longitudinal Change in Mammographic Density among ER-Positive XXXX @entity1 Using @entity3 .

answer: @entity0


abstract: UNASSIGNED: @entity3 -associated @entity4 ( @entity4 ) reductions are linked to improved @entity0 survival. We evaluated @entity4 at six time points to determine the timing of greatest reduction following @entity3 initiation. We sampled 40 Kaiser Permanente Northwest @entity2 receptor (ER)-positive @entity0 @entity1 from a prior study of @entity4 change, according to @entity3 use duration and age at diagnosis: <4 years @entity3 and  <=50 years (N = 6) or >50 years (N = 10) old; >= 4 years @entity3 and  <=50 years (N = 13) or >50 years (N = 11) old. A single reader evaluated percent @entity4 in the contralateral breast on baseline (pre-diagnosis) and five approximately yearly post-diagnostic (T1 to T5) mammograms. Mean @entity4 change was calculated. Interactions with age ( <=50 and >50 years), @entity3 duration (<4 and >= 4 years), and baseline @entity4 (tertiles) were tested in linear regression models. Overall, the largest @entity4 decline occurred by T1 (mean 4.5%) with little additional decline by T5. Declines differed by tertile of baseline @entity4 (P interaction < 0.01). In the highest tertile, the largest reduction occurred by T1 (mean 14.9%), with an additional reduction of 3.6% by T5. Changes were smaller in the middle and lowest baseline @entity4 tertiles, with cumulative reductions of 3.0% and 0.4% from baseline to T5, respectively. There were no differences by age (P interaction = 0.36) or @entity3 duration (P interaction = 0.42). Among ER-positive @entity1 treated with @entity3 and surviving >= 5 years, most of the @entity4 reduction occurred within approximately 12 months of @entity3 initiation, suggesting that @entity4 measurement at a single time point following @entity3 initiation can identify @entity1 with substantial density declines. Cancer Epidemiol Biomarkers Prev; 25(1); 1-5.   2015 AACR.

title: Longitudinal Change in Mammographic Density among ER-Positive @entity0 @entity1 Using XXXX .

answer: @entity3


abstract: UNASSIGNED: @entity3 -associated @entity4 ( @entity4 ) reductions are linked to improved @entity0 survival. We evaluated @entity4 at six time points to determine the timing of greatest reduction following @entity3 initiation. We sampled 40 Kaiser Permanente Northwest @entity2 receptor (ER)-positive @entity0 @entity1 from a prior study of @entity4 change, according to @entity3 use duration and age at diagnosis: <4 years @entity3 and  <=50 years (N = 6) or >50 years (N = 10) old; >= 4 years @entity3 and  <=50 years (N = 13) or >50 years (N = 11) old. A single reader evaluated percent @entity4 in the contralateral breast on baseline (pre-diagnosis) and five approximately yearly post-diagnostic (T1 to T5) mammograms. Mean @entity4 change was calculated. Interactions with age ( <=50 and >50 years), @entity3 duration (<4 and >= 4 years), and baseline @entity4 (tertiles) were tested in linear regression models. Overall, the largest @entity4 decline occurred by T1 (mean 4.5%) with little additional decline by T5. Declines differed by tertile of baseline @entity4 (P interaction < 0.01). In the highest tertile, the largest reduction occurred by T1 (mean 14.9%), with an additional reduction of 3.6% by T5. Changes were smaller in the middle and lowest baseline @entity4 tertiles, with cumulative reductions of 3.0% and 0.4% from baseline to T5, respectively. There were no differences by age (P interaction = 0.36) or @entity3 duration (P interaction = 0.42). Among ER-positive @entity1 treated with @entity3 and surviving >= 5 years, most of the @entity4 reduction occurred within approximately 12 months of @entity3 initiation, suggesting that @entity4 measurement at a single time point following @entity3 initiation can identify @entity1 with substantial density declines. Cancer Epidemiol Biomarkers Prev; 25(1); 1-5.   2015 AACR.

title: Longitudinal Change in Mammographic Density among ER-Positive @entity0 XXXX Using @entity3 .

answer: @entity1


abstract: OBJECTIVE: We investigated the influence of @entity1 ( @entity1 ) on @entity3 and metabolism. METHOD: There were two groups in this research; they were the research group including 115 @entity0 who were diagnosed with polysomnography and the control group of 122 healthy @entity0 . The blood pressure in the morning, plasmas @entity8 ( @entity6 ), total @entity4 (TC), @entity7 (TG), and @entity9 (UA) were measured. There were 32 moderate or severe @entity1 @entity0 and 20 healthy @entity0 were selected to be measured the mitochondrial @entity11 ( @entity11 ) with radio-immunity method. The results were analyzed with statistic method. The P < 0.05 means the significant difference. RESULT: The @entity0 ' blood pressure in the morning was significantly higher than the control healthy @entity0 . The plasmas @entity8 , total @entity4 , @entity7 , and @entity9 of the @entity1 @entity0 were all in a higher level than those of the control group healthy @entity0 . There were significant differences between the two groups. The mitochondrial @entity11 ( @entity11 ) of moderate @entity1 @entity0 or severe @entity1 @entity0 was more than that of the healthy @entity0 (P < 0.05). CONCLUSION: @entity1 is a potential risk factor on the @entity2 and the @entity5 . The mitochondrial @entity11 ( @entity11 ) may play an important role in the procedure of @entity10 .

title: [Effect of XXXX - hypopnea syndrome on @entity3 and @entity5 ].

answer: @entity1


abstract: OBJECTIVE: We investigated the influence of @entity1 ( @entity1 ) on @entity3 and metabolism. METHOD: There were two groups in this research; they were the research group including 115 @entity0 who were diagnosed with polysomnography and the control group of 122 healthy @entity0 . The blood pressure in the morning, plasmas @entity8 ( @entity6 ), total @entity4 (TC), @entity7 (TG), and @entity9 (UA) were measured. There were 32 moderate or severe @entity1 @entity0 and 20 healthy @entity0 were selected to be measured the mitochondrial @entity11 ( @entity11 ) with radio-immunity method. The results were analyzed with statistic method. The P < 0.05 means the significant difference. RESULT: The @entity0 ' blood pressure in the morning was significantly higher than the control healthy @entity0 . The plasmas @entity8 , total @entity4 , @entity7 , and @entity9 of the @entity1 @entity0 were all in a higher level than those of the control group healthy @entity0 . There were significant differences between the two groups. The mitochondrial @entity11 ( @entity11 ) of moderate @entity1 @entity0 or severe @entity1 @entity0 was more than that of the healthy @entity0 (P < 0.05). CONCLUSION: @entity1 is a potential risk factor on the @entity2 and the @entity5 . The mitochondrial @entity11 ( @entity11 ) may play an important role in the procedure of @entity10 .

title: [Effect of @entity1 - hypopnea syndrome on XXXX and @entity5 ].

answer: @entity3


abstract: OBJECTIVE: We investigated the influence of @entity1 ( @entity1 ) on @entity3 and metabolism. METHOD: There were two groups in this research; they were the research group including 115 @entity0 who were diagnosed with polysomnography and the control group of 122 healthy @entity0 . The blood pressure in the morning, plasmas @entity8 ( @entity6 ), total @entity4 (TC), @entity7 (TG), and @entity9 (UA) were measured. There were 32 moderate or severe @entity1 @entity0 and 20 healthy @entity0 were selected to be measured the mitochondrial @entity11 ( @entity11 ) with radio-immunity method. The results were analyzed with statistic method. The P < 0.05 means the significant difference. RESULT: The @entity0 ' blood pressure in the morning was significantly higher than the control healthy @entity0 . The plasmas @entity8 , total @entity4 , @entity7 , and @entity9 of the @entity1 @entity0 were all in a higher level than those of the control group healthy @entity0 . There were significant differences between the two groups. The mitochondrial @entity11 ( @entity11 ) of moderate @entity1 @entity0 or severe @entity1 @entity0 was more than that of the healthy @entity0 (P < 0.05). CONCLUSION: @entity1 is a potential risk factor on the @entity2 and the @entity5 . The mitochondrial @entity11 ( @entity11 ) may play an important role in the procedure of @entity10 .

title: [Effect of @entity1 - hypopnea syndrome on @entity3 and XXXX ].

answer: @entity5


abstract: Ten cases of advanced and metastatic @entity3 treated by weekly administration of @entity6 were studied. The @entity0 were 50-72 years of age, including 9 @entity0 and 1 @entity0 . In this study, @entity6 was administered by 1 hour intravenous infusion at a dose of 50-80 mg/m2 every week. Administration was continued for 3 weeks with 1 week rest. One to four cycles were performed at minimum. @entity6 was administered in 5 cases as 1st line treatment, 4 cases as 2nd line treatment and 1 case as 3rd line treatment. There were 2 partial responders and no complete responders, and the overall response rate was 20%. The response rate was 100% in liver, 100% in lung, 16% in lymphnodes, and 0% in peritonial dissemination. The clinical symptoms of @entity2 and @entity5 abated in one case, the size of the @entity1 decreased in one case, and a @entity4 was seen in two cases. The level of @entity1 marker was decreased in 3 out of 10 cases. Side effects included grade 3/4 @entity7 in 10% of @entity0 , and @entity8 in 50%, but @entity9 was not observed. Weekly administration of @entity6 appears to be well-tolerated and effective against advanced and metastatic @entity3 .

title: [Clinical study of weekly administration of @entity6 for advanced and metastatic XXXX ].

answer: @entity3


abstract: Ten cases of advanced and metastatic @entity3 treated by weekly administration of @entity6 were studied. The @entity0 were 50-72 years of age, including 9 @entity0 and 1 @entity0 . In this study, @entity6 was administered by 1 hour intravenous infusion at a dose of 50-80 mg/m2 every week. Administration was continued for 3 weeks with 1 week rest. One to four cycles were performed at minimum. @entity6 was administered in 5 cases as 1st line treatment, 4 cases as 2nd line treatment and 1 case as 3rd line treatment. There were 2 partial responders and no complete responders, and the overall response rate was 20%. The response rate was 100% in liver, 100% in lung, 16% in lymphnodes, and 0% in peritonial dissemination. The clinical symptoms of @entity2 and @entity5 abated in one case, the size of the @entity1 decreased in one case, and a @entity4 was seen in two cases. The level of @entity1 marker was decreased in 3 out of 10 cases. Side effects included grade 3/4 @entity7 in 10% of @entity0 , and @entity8 in 50%, but @entity9 was not observed. Weekly administration of @entity6 appears to be well-tolerated and effective against advanced and metastatic @entity3 .

title: [Clinical study of weekly administration of XXXX for advanced and metastatic @entity3 ].

answer: @entity6


abstract: Ninety-one @entity0 were treated for @entity4 of the base of the tongue between 1960 and 1974. Eighty-one of those @entity0 were treated in a consistent manner, either by radiotherapy alone or preoperative radiotherapy plus total en bloc excision with a radical neck dissection. Eighteen @entity0 were treated by radiotherapy alone (1800-7900 rads) to the primary site and bilaterally to the neck. Fifteen of these @entity0 died within five years. Sixty-three @entity0 were treated with preoperative irradiation (1800-7900 rads) followed by total primary excision with ipsilateral neck dissection. This latter group had a 50% five-year survival. Death due to uncontrolled @entity2 occurred within five years, whereas @entity3 after five years postinitial therapy was due to unrelated reasons. Unfavorable prognostic features were poor differentiation of the @entity2 , lack of histologic evidence of radiation-induced regression of the @entity2 , and more than three neck lymph node @entity1 in the initial neck dissection. Cox regression analysis showed that absence of histologic response to therapy was associated with a failure rate 4.05 times higher than that seen in @entity0 whose @entity2 did respond. @entity2 size did not affect prognosis as long as the @entity2 was technically resectable. Primary recurrences occurred in at least 20% of cases regardless of the presence or absence of surgical margin involvement.

title: XXXX : a clinicopathologic study of 81 cases.

answer: @entity4


abstract: STUDY DESIGN: Retrospective radiographic analysis. OBJECTIVE: To investigate where and to what degree the correction of @entity4 occurred in two different procedures: posterior instrumentation/fusion with an anterior release and posterior-only instrumentation/fusion with Ponte procedure. SUMMARY OF BACKGROUND DATA: Controversy remains regarding the outcome for these two procedures. The postoperative segmental disc shape change that account for @entity1 correction has not been described for either procedure. METHODS: Eleven @entity0 undergoing a thoracoscopic anterior release followed by posterior instrumentation (A + P) and 11 @entity0 having posterior-only (PO) instrumentation/fusion were retrospectively reviewed. In addition to conventional Cobb measurements, segmental measures of intradiscal angulation as well as anterior and posterior disc heights were made before and after surgery. RESULTS: The @entity3 was corrected to similar degrees in both groups (A + P vs. PO, P = 0.87). The PO group averaged 82.7      6.4   before surgery and corrected to 47.9      5.4   after surgery; while the A + P group averaged 84.9      10.2   before surgery and corrected to 48.6      5.7   after surgery. The segmental analysis demonstrated similar degrees of intradiscal angular changes between the two surgical procedures. The majority of the correction occurred at and below the apex and was independent of an anterior release. The changes in both anterior and posterior disc thicknesses were also similar between the two groups. Both groups' anterior disc spaces opened at T8 and below, whereas maximum anterior disc opening occurred at the thoracolumbar junction. To a lesser extent, the posterior disc heights were reduced, but also to similar degrees for both surgical approaches. CONCLUSION: For both surgical procedures, the majority of the @entity2 correction occurred in the lower thoracic levels and anterior disc heights increased up to twice as much as posterior disc heights shortened. The addition of the anterior release did not significantly alter the degree of correction or the disc shape changes.

title: Do discs "open" anteriorly with posterior-only correction of XXXX ?

answer: @entity4


abstract: OBJECTIVE: Laparoscopy-assisted pylorus-preserving gastrectomy (LAPPG) was introduced as a function-preserving and minimally invasive operation for @entity3 ( @entity3 ) in Japan. This study investigated the postoperative outcomes, complications, and associated risk factors of the procedure. METHODS: From January 2005 to December 2009, 307 @entity0 with @entity3 diagnosed before surgery underwent LAPPG. The postoperative outcomes and complications were assessed in this study. @entity2 were classified according to the Clavien-Dindo classification of surgical complications, and risk factors related to complications were analyzed. RESULTS: The mean operation time for LAPPG was 229.4    47.5 minutes and estimated @entity1 was 49.1    62.0 mL. The mean total number of dissected lymph nodes was 31.6    10.4, with nodal involvement observed in 25 @entity0 (8.5%). The preoperative diagnostic accuracy of @entity3 was 93.2%. Complications developed in 53 @entity0 (17.3%), and major complications, classified as grades greater than Clavien-Dindo classification IIIa, were observed in 4 @entity0 (1.3%). The most frequent complication was @entity4 , occurring in 19 @entity0 (6.2%). Body mass index (BMI) and surgical experience of LAPPG were identified as significant risk factors of @entity2 . Body mass index was related to severity of the complications. The patients' serum total protein and albumin did not change significantly after surgery. CONCLUSIONS: Laparoscopy-assisted pylorus-preserving gastrectomy is a safe operation with excellent postoperative outcomes in terms of minimized major complications based on the Clavien-Dindo classification in @entity0 with @entity3 in the middle third of the stomach. To prevent @entity2 , surgeons need to ensure an extra leaning period for LAPPG, and LAPPG should be performed cautiously in @entity0 with high BMI.

title: Postoperative outcomes and complications after laparoscopy-assisted pylorus-preserving gastrectomy for XXXX .

answer: @entity3


abstract: OBJECTIVES: To describe the results of the epidemiologic investigation of outbreaks of invasive @entity1 among attendees at daycare facilities located in 4 closed communities in Israel. STUDY DESIGN: The preschool-aged population of communities with clusters of Kingella cases had oropharyngeal cultures performed. K kingae isolates from infected @entity0 and healthy contacts were genotyped by pulsed field gel electrophoresis to determine the spread of outbreak strains. RESULTS: The affected closed communities (3 military bases and 1 "kibbutz" commune) were characterized by tight social and family networks and intensive mingling. The outbreaks affected 9 of 51 attendees (attack rate: 17.6%) age 8-19  months (median: 12  months), within a 21-day period. Cases included skeletal system infections (n  =  8) and @entity2 (n  =  1); K kingae isolates were confirmed by the use of blood culture vials and selective media. Clinical presentation was mild and acute-phase reactants were usually normal or only moderately elevated. Thirty out of 55 (54.5%) asymptomatic @entity0 carried the outbreak strains. Analysis of the 3 clusters in which the entire preschool-aged population was cultured revealed that 31 of 71 (43.7%) @entity0 younger than 24  months of age were colonized with K kingae organisms compared with 8 of 105 (7.6%) older @entity0 (P  <  .001). CONCLUSIONS: Clusters of invasive @entity1 characterized by sudden onset, high attack rate, and wide dissemination of the outbreak strain can occur in daycare facilities and closed communities. Because the mild clinical presentation of invasive @entity1 and the fastidious nature of the organism, a high index of suspicion and use of sensitive detection methods are recommended.

title: Outbreaks of Invasive XXXX in Closed Communities.

answer: @entity1


abstract: BACKGROUND: Since in clinical practice long-term @entity1 (E) treatment is frequently applied, our aim was to study the effect of concomitant @entity4 (P) administration on changes caused by long-term @entity1 treatment in the secretion of LH, FSH, PRL and GH. MATERIAL/METHODS: @entity5 ( @entity6 ), P or both in silastic capsules were implanted under the skin of prepubertal Sprague-Dawley male and female @entity0 . Animals survived for two or five months. We have also studied whether the changed hormone secretion caused by @entity6 can return to normal level 1 or 2 months after removing @entity6 capsule. RESULTS: 1.) The males more rapidly responded than females with decreasing basal LH release upon treatments. The basal FSH release was decreased only in males. The effect of @entity6 persisted in males; however, in females basal LH and FSH levels were upregulated after removal of @entity6 capsule. 2.) The basal GH levels were low in each group. The body weight and length were @entity3 by @entity6 in both genders and P little blunted this effect. The body weight and length in males remained low after removal of @entity6 capsule, in females it was nearly similar to intact @entity0 . 3.) There was no sexual dimorphism in the effect of @entity2 on PRL secretion. In both genders @entity6 extremely enhanced the PRL levels, P prevented the effect of @entity6 . PRL levels returned to intact value after removal of @entity6 influence. 4.) Removal of @entity6 capsule reversed the changes in the immunohistochemical appearance of hormone immunoreactivities. CONCLUSIONS: There was sexual dimorphism in the change of basal gonadotropic hormone and GH secretion but not of PRL upon @entity6 and @entity6 +P treatments. P was basically protective and this role may be mediated by P receptors locally in the pituitary gland.

title: Sexual dimorphism in the effect of concomitant @entity4 administration on changes caused by long-term XXXX treatment in pituitary hormone immunoreactivities of @entity0 .

answer: @entity1


abstract: BACKGROUND: Since in clinical practice long-term @entity1 (E) treatment is frequently applied, our aim was to study the effect of concomitant @entity4 (P) administration on changes caused by long-term @entity1 treatment in the secretion of LH, FSH, PRL and GH. MATERIAL/METHODS: @entity5 ( @entity6 ), P or both in silastic capsules were implanted under the skin of prepubertal Sprague-Dawley male and female @entity0 . Animals survived for two or five months. We have also studied whether the changed hormone secretion caused by @entity6 can return to normal level 1 or 2 months after removing @entity6 capsule. RESULTS: 1.) The males more rapidly responded than females with decreasing basal LH release upon treatments. The basal FSH release was decreased only in males. The effect of @entity6 persisted in males; however, in females basal LH and FSH levels were upregulated after removal of @entity6 capsule. 2.) The basal GH levels were low in each group. The body weight and length were @entity3 by @entity6 in both genders and P little blunted this effect. The body weight and length in males remained low after removal of @entity6 capsule, in females it was nearly similar to intact @entity0 . 3.) There was no sexual dimorphism in the effect of @entity2 on PRL secretion. In both genders @entity6 extremely enhanced the PRL levels, P prevented the effect of @entity6 . PRL levels returned to intact value after removal of @entity6 influence. 4.) Removal of @entity6 capsule reversed the changes in the immunohistochemical appearance of hormone immunoreactivities. CONCLUSIONS: There was sexual dimorphism in the change of basal gonadotropic hormone and GH secretion but not of PRL upon @entity6 and @entity6 +P treatments. P was basically protective and this role may be mediated by P receptors locally in the pituitary gland.

title: Sexual dimorphism in the effect of concomitant XXXX administration on changes caused by long-term @entity1 treatment in pituitary hormone immunoreactivities of @entity0 .

answer: @entity4


abstract: BACKGROUND: Since in clinical practice long-term @entity1 (E) treatment is frequently applied, our aim was to study the effect of concomitant @entity4 (P) administration on changes caused by long-term @entity1 treatment in the secretion of LH, FSH, PRL and GH. MATERIAL/METHODS: @entity5 ( @entity6 ), P or both in silastic capsules were implanted under the skin of prepubertal Sprague-Dawley male and female @entity0 . Animals survived for two or five months. We have also studied whether the changed hormone secretion caused by @entity6 can return to normal level 1 or 2 months after removing @entity6 capsule. RESULTS: 1.) The males more rapidly responded than females with decreasing basal LH release upon treatments. The basal FSH release was decreased only in males. The effect of @entity6 persisted in males; however, in females basal LH and FSH levels were upregulated after removal of @entity6 capsule. 2.) The basal GH levels were low in each group. The body weight and length were @entity3 by @entity6 in both genders and P little blunted this effect. The body weight and length in males remained low after removal of @entity6 capsule, in females it was nearly similar to intact @entity0 . 3.) There was no sexual dimorphism in the effect of @entity2 on PRL secretion. In both genders @entity6 extremely enhanced the PRL levels, P prevented the effect of @entity6 . PRL levels returned to intact value after removal of @entity6 influence. 4.) Removal of @entity6 capsule reversed the changes in the immunohistochemical appearance of hormone immunoreactivities. CONCLUSIONS: There was sexual dimorphism in the change of basal gonadotropic hormone and GH secretion but not of PRL upon @entity6 and @entity6 +P treatments. P was basically protective and this role may be mediated by P receptors locally in the pituitary gland.

title: Sexual dimorphism in the effect of concomitant @entity4 administration on changes caused by long-term @entity1 treatment in pituitary hormone immunoreactivities of XXXX .

answer: @entity0


abstract: UNASSIGNED: Response of @entity2 cells to chemotherapy-induced DNA damage is regulated by the ATM- @entity5 and @entity6 - @entity7 pathways. We investigated the association between phosphorylated @entity4 ( @entity4 ), a marker of DNA double-strand breaks that trigger the ATM- @entity5 cascade, and phosphorylated @entity7 (pChk1), with pathological complete response (pCR) in @entity0 ( @entity0 ) @entity1 treated with neoadjuvant chemotherapy. @entity4 and pChk1 were retrospectively assessed by immunohistochemistry in a series of pretreatment biopsies related to 66 @entity1 . In fifty-three @entity2 @entity3 status was negative in both the diagnostic biopsies and @entity2 , whereas in 13 cases there was a slight @entity3 expression that changed after chemotherapy. Internal validation was carried out. In the entire cohort elevated levels of @entity4 , but not pChk1, were associated with reduced pCR rate (p = 0.009). The association tested significant in both uni- and multivariate logistic regression models (OR 4.51, 95% CI: 1.39-14.66, p = 0.012, and OR 5.07, 95% CI: 1.28-20.09, p = 0.021, respectively). Internal validation supported the predictive value of the model. The predictive ability of @entity4 was further confirmed in the multivariate model after exclusion of @entity2 that underwent changes in @entity3 status during chemotherapy (OR 7.07, 95% CI: 1.39-36.02, p = 0.018). Finally, in residual diseases a significant decrease of @entity4 levels was observed (p < 0.001). Overall, @entity4 showed ability to predict pCR in @entity0 and deserves larger, prospective studies.

title: Predictive significance of DNA damage and repair biomarkers in XXXX @entity1 treated with neoadjuvant chemotherapy: An exploratory analysis.

answer: @entity0


abstract: UNASSIGNED: Response of @entity2 cells to chemotherapy-induced DNA damage is regulated by the ATM- @entity5 and @entity6 - @entity7 pathways. We investigated the association between phosphorylated @entity4 ( @entity4 ), a marker of DNA double-strand breaks that trigger the ATM- @entity5 cascade, and phosphorylated @entity7 (pChk1), with pathological complete response (pCR) in @entity0 ( @entity0 ) @entity1 treated with neoadjuvant chemotherapy. @entity4 and pChk1 were retrospectively assessed by immunohistochemistry in a series of pretreatment biopsies related to 66 @entity1 . In fifty-three @entity2 @entity3 status was negative in both the diagnostic biopsies and @entity2 , whereas in 13 cases there was a slight @entity3 expression that changed after chemotherapy. Internal validation was carried out. In the entire cohort elevated levels of @entity4 , but not pChk1, were associated with reduced pCR rate (p = 0.009). The association tested significant in both uni- and multivariate logistic regression models (OR 4.51, 95% CI: 1.39-14.66, p = 0.012, and OR 5.07, 95% CI: 1.28-20.09, p = 0.021, respectively). Internal validation supported the predictive value of the model. The predictive ability of @entity4 was further confirmed in the multivariate model after exclusion of @entity2 that underwent changes in @entity3 status during chemotherapy (OR 7.07, 95% CI: 1.39-36.02, p = 0.018). Finally, in residual diseases a significant decrease of @entity4 levels was observed (p < 0.001). Overall, @entity4 showed ability to predict pCR in @entity0 and deserves larger, prospective studies.

title: Predictive significance of DNA damage and repair biomarkers in @entity0 XXXX treated with neoadjuvant chemotherapy: An exploratory analysis.

answer: @entity1


abstract: In Latin America and the Caribbean, around 195 million @entity0 live in poverty, a situation that increases the burden of some @entity1 . @entity4 , in particular, are often restricted to poor, marginalized sections of the population. Tools exist to combat these diseases, making it imperative to work towards their elimination. In 2009, the Pan American Health Organization (PAHO) received a mandate to support the countries in the Region in eliminating @entity4 and other poverty-related @entity3 . The objective of this study is to analyze the presence of selected diseases using geo-processing techniques. Five diseases with information available at the first sub-national level (states) were mapped, showing the presence of the disease ("hotspots") and overlap of diseases ("major hotspots"). In the 45 countries/territories (approximately 570 states) of the Region, there is: lymphatic filariasis in four countries (29 states), @entity6 in six countries (25 states), @entity5 in four countries (39 states), @entity7 in three countries (29 states), and @entity0 rabies transmitted by @entity2 in ten countries (20 states). Of the 108 states with one or more of the selected diseases, 36 states present the diseases in overlapping areas ("major hotspots"). Additional information about soil-transmitted helminths was included. The analysis suggests a majority of the selected diseases are not widespread and can be considered part of an unfinished agenda with elimination as a goal. Integrated plans and a comprehensive approach, ensuring access to existing diagnostic and treatment methods, and establishing a multi-sectoral agenda that addresses social determinants, including access to adequate water and sanitation, are required. Future studies can include additional diseases, socio-economic and environmental variables.

title: Elimination of XXXX in latin america and the Caribbean: a mapping of selected diseases.

answer: @entity4


abstract: OBJECTIVES: This study sought to investigate the effect of soft callus removal and reapplication in a @entity0 closed femur @entity1 model. We hypothesized that removing soft callus will impair @entity1 healing, whereas reapplication will facilitate healing. METHODS: A closed midshaft femur @entity1 was created in 78 @entity0 and stabilized with an intramedullary wire. Seven days later, @entity0 were equally divided and @entity1 surgically exposed. In the control group, no callus was removed, whereas in the callus removal group CR(-) group, the callus was removed and in the callus replaced group CR(+), callus was removed and replaced. Half of the @entity0 were killed at 4 and 7 weeks. @entity1 healing was graded with radiographs and callus volume measured with micro-CT. Mechanical torsion properties were measured, and histologic analysis was conducted. RESULTS: At both end points, evidence of @entity2 was found on radiographs and micro-CT in CR(-) @entity0 (P = 0.0001), whereas CR(+) @entity0 showed normal @entity1 healing compared with controls. The normalized callus volume was similar in all groups at both end points. At 7 weeks, the maximum stiffness in CR(-) @entity0 was 68% less than control (P = 0.0001). Stiffness increased 55% in CR(+) @entity0 from CR(-) @entity0 (P = 0.0017). Histology supported our findings with complete endochondral ossification in CR(+) @entity0 but wide areas of hyaline cartilage in CR(-) @entity0 at 7 weeks. CONCLUSIONS: Removal of soft callus in a @entity0 model delays @entity1 healing at early and late time points, whereas replacement mitigates these negative consequences. Replacing the soft callus should be considered in all osteosynthesis procedures.

title: Augmentation of XXXX Healing Using Soft Callus.

answer: @entity1


abstract: PURPOSE: @entity1 care is a standard feature of high quality care. In many centers, the multidisciplinary meeting (MDM) is an integral component. A qualitative study was performed to explore health professionals' attitudes towards this model of care, the decision making processes, and dynamics among team members. METHODS: A series of focus groups was conducted with health professionals who attend MDMs at our institution. Focus groups followed a semistructured format with open-ended questions. A thematic analysis was performed. RESULTS: Four focus groups were held, attended by 23 @entity0 including allied health professionals, specialist nurses, medical oncologists, and surgeons. All @entity0 believed the primary objective of the MDM was to develop an individualized treatment plan. Several other key themes emerged. The MDM provided opportunities to improve communication, efficiency, and education as well as enhance professional relationships. Medical information was prioritized ahead of psychosocial details, with allied health professionals describing difficulty contributing to MDM discussion. @entity0 attendance at MDMs was opposed by health professionals because of concerns about the @entity0 's ability to cope with the information discussed and the effect their presence would have on the dynamics of the decision-making process. CONCLUSION: Health professionals endorse MDMs as a useful tool in treating @entity0 with @entity1 . Within this forum, both opportunities and constrains exist, with many benefits extending beyond the meeting itself into other clinical areas. Further study is warranted to establish an evidence base to ensure that both the possibilities and the limitations of this model of care are fully understood.

title: Team dynamics, decision making, and attitudes toward multidisciplinary XXXX meetings: health professionals' perspectives.

answer: @entity1


abstract: A community @entity2 clinic, through cooperation with its parent health care system, developed a @entity1 multidisciplinary clinic (MDC) to enhance @entity0 care and prevent out-migration to competing health care systems. The local medical and radiation oncologists collaborated with a thoracic surgeon from the tertiary care hospital in establishing the lung MDC. All the participating physicians are employed by the health care system. A @entity2 care coordinator assured that all necessary tests were obtained and available to the physicians at least 1 day before the clinic. The multidisciplinary team also included a pulmonologist and met every third week. Other sub-specialists were involved as necessary. Final treatment recommendations using National Comprehensive @entity2 Network guidelines were made for each @entity0 at the MDC visit. This clinic, once established, resulted in significant improvements in the quality of care, @entity0 satisfaction and retention of @entity0 . Time from diagnosis to initiation of treatment was reduced to a mean of 18 days from a mean of 24 days. The community @entity2 clinic had an @entity1 @entity0 care by 28% and a 9.1% increase in gross revenue. The tertiary care hospital benefited by providing all @entity0 with definitive surgery, including minimally invasive surgery. The tertiary hospital thoracic surgeon had a 75% increase in referrals from the lung MDC geographic area over the previous year. This collaboration in the development of MDCs demonstrates how @entity0 , caregivers, and the health care system benefit from MDCs.

title: Establishing a community-based XXXX multidisciplinary clinic as part of a large integrated health care system: aurora health care.

answer: @entity1


abstract: UNASSIGNED: The @entity3 ( @entity3 ) is a G protein-coupled receptor (GPCR) that is member of the @entity1 -rich repeat subfamily (LGR). In the absence of crystal structure, the success of rational design of ligands targeting the receptor internal cavity depends on the quality of the @entity3 models built. In this subfamily, @entity4 are characterized by the absence of @entity2 compared to most receptors, raising the question of the structural conformation of these helices. To gain insight into the structural properties of these helices, we carried out bioinformatics and experimental studies. Evolutionary analysis of the LGR family revealed a deletion in @entity4 but provided no information on TM2. Wild type residues at positions 2.58, 2.59 or 2.60 in TM2 and/or at position 5.50 in @entity4 were substituted to @entity2 . Depending on the position of the @entity2 substitution, different effects were observed on membrane expression, glycosylation, constitutive @entity0 activity and responses to thyrotropin. Only @entity2 substitution at position 2.59 maintained complex glycosylation and high membrane expression, supporting occurrence of a bulged TM2. The @entity3 transmembrane domain was modeled by homology with the orexin 2 receptor, using a protocol that forced the deletion of one residue in the @entity4 bulge of the template. The stability of the model was assessed by molecular dynamics simulations. @entity4 straightened during the equilibration phase and was stable for the remainder of the simulations. Our data support a structural model of the @entity3 transmembrane domain with a bulged TM2 and a straight @entity4 that is specific of glycoprotein hormone receptors.

title: Molecular Insights into the Transmembrane Domain of the XXXX .

answer: @entity3


abstract: The aim of this study was to evaluate the pharmacokinetic parameters, efficacy and @entity2 of a @entity3 and @entity4 combination in metastatic @entity0 @entity1 previously treated with @entity6 . A population of 40 @entity1 was analyzed; 30 @entity1 (75%) had visceral metastases as the dominant site of disease, including 20 @entity1 (50%) with liver metastases. Three or more organs were involved in 43% of @entity1 . All @entity1 had received prior @entity6 therapy. Five @entity1 (12%) had primary resistant disease, 10 @entity1 (25%) secondary resistant disease and 25 @entity1 (63%) had progressive metastatic @entity0 after first-line chemotherapy. @entity3 and @entity4 were given at 80 mg/m2 and 20 mg/m2 i.v., respectively, on day 1 every 3 weeks. After a median of 5 cycles, it was found that 5 @entity1 had a complete remission (13%), 19 a partial remission (48%), 9 had stable disease (22%) and 7 had progressive disease (17%). Response rates in @entity1 with visceral and liver metastases were 57% and 50%, respectively. After a median follow-up of 24 months (13-36), median time to progression was 8.5 months and median overall survival 17 months. Grade 4 @entity5 was observed in 78% of courses ( @entity5 in 9%). Possible pharmacokinetic interactions were studied in 23 @entity1 by administering @entity3 immediately followed by @entity4 (protocol A) or @entity4 followed by @entity3 (protocol B). @entity1 in protocol B had significantly higher @entity4 plasma levels and more pronounced @entity5 . @entity3 plus @entity4 is an effective combination in @entity6 resistant/relapsed metastatic @entity0 . The administration sequence @entity3 --> @entity4 is safer than the reverse order.

title: Clinical data and pharmacokinetics of a @entity3 - @entity4 combination in @entity6 resistant/ relapsed metastatic XXXX .

answer: @entity0


abstract: The aim of this study was to evaluate the pharmacokinetic parameters, efficacy and @entity2 of a @entity3 and @entity4 combination in metastatic @entity0 @entity1 previously treated with @entity6 . A population of 40 @entity1 was analyzed; 30 @entity1 (75%) had visceral metastases as the dominant site of disease, including 20 @entity1 (50%) with liver metastases. Three or more organs were involved in 43% of @entity1 . All @entity1 had received prior @entity6 therapy. Five @entity1 (12%) had primary resistant disease, 10 @entity1 (25%) secondary resistant disease and 25 @entity1 (63%) had progressive metastatic @entity0 after first-line chemotherapy. @entity3 and @entity4 were given at 80 mg/m2 and 20 mg/m2 i.v., respectively, on day 1 every 3 weeks. After a median of 5 cycles, it was found that 5 @entity1 had a complete remission (13%), 19 a partial remission (48%), 9 had stable disease (22%) and 7 had progressive disease (17%). Response rates in @entity1 with visceral and liver metastases were 57% and 50%, respectively. After a median follow-up of 24 months (13-36), median time to progression was 8.5 months and median overall survival 17 months. Grade 4 @entity5 was observed in 78% of courses ( @entity5 in 9%). Possible pharmacokinetic interactions were studied in 23 @entity1 by administering @entity3 immediately followed by @entity4 (protocol A) or @entity4 followed by @entity3 (protocol B). @entity1 in protocol B had significantly higher @entity4 plasma levels and more pronounced @entity5 . @entity3 plus @entity4 is an effective combination in @entity6 resistant/relapsed metastatic @entity0 . The administration sequence @entity3 --> @entity4 is safer than the reverse order.

title: Clinical data and pharmacokinetics of a @entity3 - @entity4 combination in XXXX resistant/ relapsed metastatic @entity0 .

answer: @entity6


abstract: The aim of this study was to evaluate the pharmacokinetic parameters, efficacy and @entity2 of a @entity3 and @entity4 combination in metastatic @entity0 @entity1 previously treated with @entity6 . A population of 40 @entity1 was analyzed; 30 @entity1 (75%) had visceral metastases as the dominant site of disease, including 20 @entity1 (50%) with liver metastases. Three or more organs were involved in 43% of @entity1 . All @entity1 had received prior @entity6 therapy. Five @entity1 (12%) had primary resistant disease, 10 @entity1 (25%) secondary resistant disease and 25 @entity1 (63%) had progressive metastatic @entity0 after first-line chemotherapy. @entity3 and @entity4 were given at 80 mg/m2 and 20 mg/m2 i.v., respectively, on day 1 every 3 weeks. After a median of 5 cycles, it was found that 5 @entity1 had a complete remission (13%), 19 a partial remission (48%), 9 had stable disease (22%) and 7 had progressive disease (17%). Response rates in @entity1 with visceral and liver metastases were 57% and 50%, respectively. After a median follow-up of 24 months (13-36), median time to progression was 8.5 months and median overall survival 17 months. Grade 4 @entity5 was observed in 78% of courses ( @entity5 in 9%). Possible pharmacokinetic interactions were studied in 23 @entity1 by administering @entity3 immediately followed by @entity4 (protocol A) or @entity4 followed by @entity3 (protocol B). @entity1 in protocol B had significantly higher @entity4 plasma levels and more pronounced @entity5 . @entity3 plus @entity4 is an effective combination in @entity6 resistant/relapsed metastatic @entity0 . The administration sequence @entity3 --> @entity4 is safer than the reverse order.

title: Clinical data and pharmacokinetics of a @entity3 - XXXX combination in @entity6 resistant/ relapsed metastatic @entity0 .

answer: @entity4


abstract: The aim of this study was to evaluate the pharmacokinetic parameters, efficacy and @entity2 of a @entity3 and @entity4 combination in metastatic @entity0 @entity1 previously treated with @entity6 . A population of 40 @entity1 was analyzed; 30 @entity1 (75%) had visceral metastases as the dominant site of disease, including 20 @entity1 (50%) with liver metastases. Three or more organs were involved in 43% of @entity1 . All @entity1 had received prior @entity6 therapy. Five @entity1 (12%) had primary resistant disease, 10 @entity1 (25%) secondary resistant disease and 25 @entity1 (63%) had progressive metastatic @entity0 after first-line chemotherapy. @entity3 and @entity4 were given at 80 mg/m2 and 20 mg/m2 i.v., respectively, on day 1 every 3 weeks. After a median of 5 cycles, it was found that 5 @entity1 had a complete remission (13%), 19 a partial remission (48%), 9 had stable disease (22%) and 7 had progressive disease (17%). Response rates in @entity1 with visceral and liver metastases were 57% and 50%, respectively. After a median follow-up of 24 months (13-36), median time to progression was 8.5 months and median overall survival 17 months. Grade 4 @entity5 was observed in 78% of courses ( @entity5 in 9%). Possible pharmacokinetic interactions were studied in 23 @entity1 by administering @entity3 immediately followed by @entity4 (protocol A) or @entity4 followed by @entity3 (protocol B). @entity1 in protocol B had significantly higher @entity4 plasma levels and more pronounced @entity5 . @entity3 plus @entity4 is an effective combination in @entity6 resistant/relapsed metastatic @entity0 . The administration sequence @entity3 --> @entity4 is safer than the reverse order.

title: Clinical data and pharmacokinetics of a XXXX - @entity4 combination in @entity6 resistant/ relapsed metastatic @entity0 .

answer: @entity3


abstract: PURPOSE: To report visual outcomes in @entity0 undergoing proton beam irradiation of @entity1 located within 1 disc diameter of the fovea. DESIGN: Retrospective review. @entity0 : @entity0 with @entity2 involving the fovea treated with proton beam therapy between 1975 and  2009. METHODS: Three hundred fifty-one @entity0 with @entity2 located 1 disc diameter (DD) or less from the fovea and more than 1 DD away from the optic nerve were included in this study. In a subgroup of 203 of the @entity0 with small and medium @entity2 , the effect of a reduced dose of radiation, 50 Gy (relative biological effectiveness [RBE]) versus 70 Gy (RBE), on visual outcomes was analyzed. The Kaplan-Meier method and Cox regression analysis were performed to calculate cumulative rates of @entity3 and to assess risk factors for @entity3 , respectively. MAIN OUTCOME MEASURES: Visual acuity and radiation complications, which included radiation @entity4 , papillopathy, @entity5 , and rubeosis, were assessed. RESULTS: Three hundred fifty-one @entity0 were included in this study with a mean follow-up time of 68.7 months. More than one-third of @entity0 (35.5%) retained 20/200 or better vision 5 years after proton beam irradiation. For those @entity0 with a baseline visual acuity of 20/40 or better, 16.2% of @entity0 retained this level of vision 5 years after proton beam irradiation. @entity1 height less than 5 mm and baseline visual acuity 20/40 or better were associated significantly with a better visual outcome (P < 0.001). More than two-thirds (70.4%) of @entity0 receiving 50 Gy (RBE) and nearly half (45.1%) of @entity0 receiving 70 Gy (RBE) retained 20/200 or better vision 5 years after treatment, but this difference was not significant. Approximately 20% of @entity0 with these smaller macular @entity1 retained 20/40 vision or better 5 years after irradiation. CONCLUSIONS: The results of this retrospective analysis demonstrate that despite receiving a full dose of radiation to the fovea, many @entity0 with @entity2 with foveal involvement maintain useful vision. A radiation dose reduction from 70 to 50 Gy (RBE) did not seem to increase the proportion of @entity0 who retain usable vision.

title: Visual Outcomes after Proton Beam Irradiation for XXXX Involving the Fovea.

answer: @entity2


abstract: Laterocollis, as a symptom of @entity2 may be due to abnormal contraction of the levator scapulae muscle (LSM). The purpose of this study is to define the effects of selective peripheral denervation of LSM in @entity0 with @entity3 .The clinical records of 10 @entity0 who underwent LSM denervation for laterocollic torticollis were reviewed. Preoperatively, all @entity0 showed sustained lateral tilt of the head and elevation of the shoulder. Abnormal contraction of LSM was observed and the muscle was denervated surgically in the posterior cervical triangle. The mean age at operation was 38.4 years (range, 20-58 years) and the mean duration of the symptom ranged from 14 to 80 months (mean, 41months). The postoperative follow up ranged from 6 to 72 months (mean, 29.4months). The cervical @entity1 rating score of Tsui was 10.8 on average before the operation, and the postoperative follow up score was 1.3. According to the changes of the rating score, success rates, including excellent and good results, were 40% and 60%, respectively. Five @entity0 (50%) postoperatively showed transient dysaesthesia in the neck. There was no disturbance of shoulder elevation or arm raising. When abnormal contraction of LSM is responsible for laterocollis in @entity0 with cervical @entity1 , selective peripheral denervation of this muscle is a safe and effective procedure for alleviation of the symptom.

title: Selective peripheral denervation of the levator scapulae muscle for XXXX .

answer: @entity3


abstract: BACKGROUND: Routine staging imaging for @entity0 is not recommended. Despite this, there is clinical practice variation with imaging studies obtained for asymptomatic @entity1 with a positive sentinel node (SN+). We characterize the utility, cost, and clinical implications of imaging studies obtained in asymptomatic SN+ @entity1 . METHODS: A retrospective review was performed of asymptomatic, clinically node-negative @entity1 who were found to have a positive sentinel node after surgery. The type of imaging, subsequent tests/interventions, frequency of additional malignancy detected, and costs were recorded. RESULTS: From April 2009 to April 2013, a total of 50 of 113 (44%) asymptomatic @entity1 underwent staging imaging for a positive sentinel node; 11 (22%) @entity1 had at least 1 subsequent imaging study or diagnostic intervention. No instance of metastatic @entity0 was identified, with a total cost of imaging calculated at  116,905. CONCLUSIONS: Staging imaging for asymptomatic SN+ @entity0 demonstrates clinical variation. These tests were associated with low utility, increased costs, and frequent false positives leading to subsequent testing/intervention. Evidence-based standardization may help increase quality by decreasing unnecessary variation and cost.

title: Value analysis of postoperative staging imaging for asymptomatic, XXXX : implications of clinical variation on utility and cost.

answer: @entity0


abstract: @entity1 ( @entity1 ) is a recently described entity in the differential diagnosis of @entity0 . It is notable for a characteristic t(12;15)(p13;q25) translocation that results in a unique fusion protein, @entity4 - @entity5 . While several studies have retrospectively identified this translocation in cases previously diagnosed as a different @entity0 , there have been relatively few cases where this translocation was identified on initial pathology results, and fewer still in a pediatric population. We present a case of a 15 year old female with a slowly enlarging, painless, left facial mass. MRI demonstrated a cystic mass extending into the deep lobe of the parotid, and she underwent parotidectomy. The @entity0 cells stained positive for @entity2 and @entity3 . @entity4 translocation was present, confirming the diagnosis. @entity1 is a recently described @entity0 of the salivary glands, which often masquerades as more common primary @entity0 and cysts. More research is needed to characterize the typical behavior of this @entity0 and the optimal treatment regimen. With identification of its characteristic translocation, mammary analogue @entity1 can be easily differentiated from its more prevalent counterparts, and should therefore remain within the differential of the pathologist and head and neck surgeon.

title: A pediatric case of mammary analogue XXXX within the parotid.

answer: @entity1


abstract: INTRODUCTION: @entity1 in childhood is predictive of @entity1 in adulthood and it is associated with adverse health effect apparent since childhood; however, the joint assessment of @entity1 and adverse events among @entity0 in clinical settings is unusual. OBJECTIVES: to assess the association of overweight and @entity1 , @entity5 , and excess body fat with systolic [ @entity7 ] and diastolic [ @entity8 ] blood pressure, lipid profile and @entity4 levels; and to identify the best anthropometric indicator of such events. MATERIAL AND METHODS: we conducted a cross-sectional study in a sample of 412 schoolchildren. The presence of overweight and @entity1 , @entity5 and excess body fat was determined among all @entity0 ; levels of total @entity3 , @entity6 , high and low density lipoproteins, and @entity4 were measured in a subsample (n = 133). The associations of interest were assessed using adjusted linear and logistic regression models. RESULTS: 33% of the @entity0 were overweight or @entity1 . Overall, overweight, @entity1 , @entity5 , and excess body fat were associated with elevated @entity7 and @entity8 and with a lipid profile and @entity4 levels that could indicate health risks among these @entity0 . Overweight and @entity1 were the best predictors of such events. CONCLUSIONS: among these school-aged @entity0 , we observed that @entity1 was associated with high odds of having adverse health outcomes such as @entity2 , lipids and @entity4 . Such adverse events can be predicted by the presence of @entity1 measured by BMI, which is a noninvasive, inexpensive and easy to implement measure.

title: [ANTHROPOMETRIC INDICATORS AND CARDIOMETABOLIC EVENTS AMONG SCHOOLAGED XXXX FROM SONORA, MEXICO].

answer: @entity0


abstract: OBJECTIVE: To evaluate the characteristics of metabolism in @entity0 with @entity2 complicated by @entity1 ( @entity1 ), and the effects of nutritional support in different periods. METHODS: In 32 @entity0 out of 66 @entity0 suffering from @entity1 nutritional support was given through different channels according to different disease stages. In the first period, total parenteral nutrition (TPN) should be implemented when acute stress was just over and the functions of gastro-intestinal system was still in a bad condition. During the second period, TPN and enteral nutrition(EN) could be instituted at the same time, when the state of illness was under control. In the third period, if the condition of the @entity0 was totally controlled, and the function of stomach and intestine had completely recovered, total EN could be given after a transitional period. RESULTS: In these 32 @entity0 , 23 @entity0 were cured successfully and 9 @entity0 died; the mortality was 28.12%. In those 34 @entity0 treated with conventional methods, 19 @entity0 were cured while 15 @entity0 died, and the mortality was 44.11% (P<0.01). CONCLUSION: When @entity1 occurred, metabolism is disturbed, and the body is unable to utilize the supplied nutrients and to get rid of the catabolic products. There fore, it seemed to be necessary to give nutrition support in different manner during different periods of the disease. Otherwise, the disease might be aggravated.

title: [Characteristics of metabolism and nutrition support during different periods in XXXX complicated by @entity1 ].

answer: @entity2


abstract: OBJECTIVE: To evaluate the characteristics of metabolism in @entity0 with @entity2 complicated by @entity1 ( @entity1 ), and the effects of nutritional support in different periods. METHODS: In 32 @entity0 out of 66 @entity0 suffering from @entity1 nutritional support was given through different channels according to different disease stages. In the first period, total parenteral nutrition (TPN) should be implemented when acute stress was just over and the functions of gastro-intestinal system was still in a bad condition. During the second period, TPN and enteral nutrition(EN) could be instituted at the same time, when the state of illness was under control. In the third period, if the condition of the @entity0 was totally controlled, and the function of stomach and intestine had completely recovered, total EN could be given after a transitional period. RESULTS: In these 32 @entity0 , 23 @entity0 were cured successfully and 9 @entity0 died; the mortality was 28.12%. In those 34 @entity0 treated with conventional methods, 19 @entity0 were cured while 15 @entity0 died, and the mortality was 44.11% (P<0.01). CONCLUSION: When @entity1 occurred, metabolism is disturbed, and the body is unable to utilize the supplied nutrients and to get rid of the catabolic products. There fore, it seemed to be necessary to give nutrition support in different manner during different periods of the disease. Otherwise, the disease might be aggravated.

title: [Characteristics of metabolism and nutrition support during different periods in @entity2 complicated by XXXX ].

answer: @entity1


abstract: WHAT IS KNOWN AND OBJECTIVE: @entity4 is an important drug for the prevention of @entity3 events such as @entity1 in @entity0 with @entity2 ( @entity2 ). However, it is commonly implicated in major adverse drug events, which may result in reluctance to prescribe @entity4 , especially in the institutionalised elderly population. This study aimed to assess the current trends in the antithrombotic management of @entity2 in aged care facilities (ACFs) in Tasmania, Australia, and to compare this with current recommendations. METHODS: We performed a non-experimental, retrospective cohort study designed to evaluate antithrombotic usage for @entity2 in @entity5 residents in Tasmania. Residents with @entity2 were identified on a @entity0 -by- @entity0 basis from residential case-note summaries collected from 29 of the 64 ACFs in Tasmania. The CHADS-2 score and the presence or absence of documented contraindications were used to determine the appropriateness of the current antithrombotic therapy prescribed. RESULTS AND DISCUSSION: Fifteen per cent (262/1737) of the @entity5 residents were diagnosed with @entity2 . Nine per cent of the residents with @entity2 had a contraindication to antithrombotic therapy (either @entity4 or antiplatelet therapy). Eighty-one per cent of residents were eligible for treatment with @entity4 according to the CHADS-2 score and did not appear to have a contraindication to @entity4 . Of these, only 38% were prescribed @entity4 ; 16% (40/255) did not receive any antithrombotic treatment, despite being eligible for treatment with @entity4 or antiplatelet therapy. Residents who did not receive any antithrombotic treatment or who received antiplatelet treatment were significantly older than those treated with anticoagulants. WHAT IS NEW AND CONCLUSION: Our results indicate that antithrombotic therapy, particularly @entity4 , is underused in @entity5 -dwelling elderly @entity0 who are eligible for treatment.

title: Evaluation of antithrombotic usage for XXXX in aged care facilities.

answer: @entity2


abstract: BACKGROUND: Scaling left atrial (LA) size remains a challenge. An allometric model using body weight (BW) as scaling variable was recently proposed. We sought to examine the performance of this model in an @entity0 population. METHODS: A total of 266 consecutive overweight (110) and @entity0 subjects (class I, II, and III @entity0 81, 47, and 28, respectively) were studied; 46 normal subjects with normal body mass index (BMI) served as controls. @entity2 ( @entity2 ) was scaled to BW, body surface area (BSA), BMI and height, respectively, using both isometric and allometric models. RESULTS: There were no significant differences in age, gender, or height among the five groups. The prevalence of comorbid conditions, wall thickness, E/E' and @entity2 measures increased significantly with increasing weight group (P < 0.01-0.001). With the isometric model, @entity2 corrected by BW, BSA, and BMI significantly but @entity1 decreased across the groups (P < 0.05-0.001). With the allometric model, @entity2 overcorrection by BM, BSA, and BMI was improved, but remained in the class III @entity0 group. In contrast, scaling @entity2 to height showed significant and graded increase across the five groups in accordance with the increases of BMI, E/E' and the prevalence of comorbid conditions. CONCLUSION: All isometric models that correct @entity2 by BW or BW containing variables underestimate LA size in overweight and @entity0 groups. The allometric model using height provides more consistent results and should be preferred to models using BW or BW containing variables in scaling @entity2 in @entity0 population.

title: Allometric model improves scaling of left atrial size in XXXX population: the use of body weight containing variables is challenged.

answer: @entity0


abstract: The study includes 10 @entity0 affected by @entity5 of @entity1 who underwent surgery. The @entity5 involved the "non coronary" sinus in 5 cases and the right coronary sinus in 5. All the @entity5 prolapsed into the right cardiac chambers. @entity3 were present in 6 @entity0 . 4 @entity0 were asymptomatic, 2 were in NYHA class III and 4 in class IV and one was in @entity6 . Indications for surgery were hemodynamic impairment due to the shunt and/or associated anomalies. Surgical treatment included resection of the @entity5 , suture of its orifice and correction of associated @entity3 . @entity2 only occurred in one @entity0 , who arrived at surgery in @entity6 . 8 @entity0 were followed-up for a mean period of 40 months (range 11 to 84 months), after operation: satisfactory clinical conditions were found in all of them. A mild @entity4 was only observed in one @entity0 , 8 years after surgery.

title: [ XXXX . Study of ten treated subjects (author's transl)].

answer: @entity5


abstract: AIMS: To compare kinematic parameters (ie, amplitude, velocity, cycle frequency) of chewing and @entity2 characteristics in a group of female myofascial @entity4 ( @entity4 ) @entity0 with an age-matched control female group, and to study correlations between psychological variables and kinematic variables of chewing. METHODS: Twenty-nine female @entity0 were recruited. All @entity0 were categorized according to the Research Diagnostic Criteria for @entity4 ( @entity5 / @entity4 ) into control (n = 14, mean age 28.9 years, SD 5.0 years) or @entity4 (n = 15, mean age 31.3 years, SD 10.7) groups. Jaw movements were recorded during free gum chewing and chewing standardized for timing. @entity0 completed the @entity3 , @entity1 , and Stress Scales (DASS-42), the @entity2 Catastrophizing Scale (PCS), the Fear of @entity2 Questionnaire-III (FPQ-III), and the @entity2 Self-Efficacy Questionnaire (PSEQ). Statistical analyses involved evaluation for group differences, and correlations between kinematic variables and psychological questionnaire scores (eg, @entity3 , @entity1 , stress) and @entity2 intensity ratings. RESULTS: Velocity and amplitude of standardized (but not free) chewing were significantly greater (P < .05) in the @entity4 group than the control group. There were significant (P < .05) positive correlations between @entity2 intensity ratings and velocity and amplitude of standardized chewing but not free chewing. There were significant (P < .05) positive correlations between @entity3 and jaw amplitude and stress and jaw velocity for standardized but not free chewing. CONCLUSION: This exploratory study has provided data suggesting that psychological factors, manifesting in @entity3 and stress, play a role in influencing the association between @entity2 and motor activity.

title: Chewing in XXXX @entity0 : an exploratory study of an association with some psychological variables.

answer: @entity4


abstract: AIMS: To compare kinematic parameters (ie, amplitude, velocity, cycle frequency) of chewing and @entity2 characteristics in a group of female myofascial @entity4 ( @entity4 ) @entity0 with an age-matched control female group, and to study correlations between psychological variables and kinematic variables of chewing. METHODS: Twenty-nine female @entity0 were recruited. All @entity0 were categorized according to the Research Diagnostic Criteria for @entity4 ( @entity5 / @entity4 ) into control (n = 14, mean age 28.9 years, SD 5.0 years) or @entity4 (n = 15, mean age 31.3 years, SD 10.7) groups. Jaw movements were recorded during free gum chewing and chewing standardized for timing. @entity0 completed the @entity3 , @entity1 , and Stress Scales (DASS-42), the @entity2 Catastrophizing Scale (PCS), the Fear of @entity2 Questionnaire-III (FPQ-III), and the @entity2 Self-Efficacy Questionnaire (PSEQ). Statistical analyses involved evaluation for group differences, and correlations between kinematic variables and psychological questionnaire scores (eg, @entity3 , @entity1 , stress) and @entity2 intensity ratings. RESULTS: Velocity and amplitude of standardized (but not free) chewing were significantly greater (P < .05) in the @entity4 group than the control group. There were significant (P < .05) positive correlations between @entity2 intensity ratings and velocity and amplitude of standardized chewing but not free chewing. There were significant (P < .05) positive correlations between @entity3 and jaw amplitude and stress and jaw velocity for standardized but not free chewing. CONCLUSION: This exploratory study has provided data suggesting that psychological factors, manifesting in @entity3 and stress, play a role in influencing the association between @entity2 and motor activity.

title: Chewing in @entity4 XXXX : an exploratory study of an association with some psychological variables.

answer: @entity0


abstract: It is necessary to understand the full burden of illness of a disease before the value of interventions can be assessed. @entity2 ( @entity2 ) has an impact on a variety of stakeholders, including @entity0 , healthcare systems, and society as a whole. This overview discusses the societal and @entity0 perspectives, distinguishing several domains of impact. Epidemiology is important from a societal perspective, as it affects the total impact on health and costs related to @entity2 and influences healthcare organization priorities. Co-morbidities, such as @entity1 , are important factors contributing to the impact of @entity2 . The impact on health is, naturally, relevant to both @entity0 and society as a whole, and is summarized by health-related quality-of-life measures from the point of view of the @entity0 and by utilities from the societal perspective. Similarly, work participation is important for both @entity0 and society. Withdrawal from the labor force and short- and long-term sick leave are extensively studied in @entity2 and lead to substantial productivity costs at the societal level and to @entity3 for @entity0 . In addition, the recent concept of presenteeism, which reflects the problems that @entity0 experience while at work, is considered. Finally, the costs of illness of @entity2 are summarized. Societal costs are mainly driven by the costs of drug treatment and inpatient care, including surgery. @entity0 and family costs are mainly driven by the need for formal and informal care. Overall, @entity2 has a significant impact on the health of and costs to @entity0 and society, suggesting that effective interventions to reduce the impact are of value.

title: The burden of illness of XXXX .

answer: @entity2


abstract: INTRODUCTION: @entity2 ( @entity2 ) is one of the most frequent @entity1 , in which the potentially curative treatment is surgery: partial surgical resection or liver transplant. OBJECTIVES: To determine the morbidity and mortality, survival, and their associated factors in @entity0 with @entity2 , according to the type of surgical treatment: partial surgical resection or liver transplant. MATERIAL AND METHODS: A retrospective, observational follow-up study of @entity2 @entity0 diagnosed and treated from June 1994 to December 2007. A descriptive analysis of the variables was performed, as well as a Kaplan- Meier survival analysis and Cox regression. RESULTS: The incidence of @entity1 recurrence in the 150 transplant @entity0 was 13.3%, with a survival at 1, 3, and 5 years of 89.3%, 73.1% and 61.4%, respectively. The multivariate analysis showed that only the histological grade/differentiation was an independent risk factor. In the 33 @entity0 with partial surgical resection, the incidence of @entity1 was 51.5%, with a survival at 1, 3, and 5 years of 90.9%, 60.2%, and 38.6%, respectively. A significantly higher mortality was observed in @entity0 with @entity1 and TNM staging. CONCLUSIONS: The survival throughout follow-up was higher in liver transplant, and @entity1 recurrence was more frequent in @entity0 with partial surgical resection. The survival results in transplanted @entity0 are consistent with the Spanish and European Liver Transplant Register and with the United Network for Organ Sharing register.

title: [Surgical treatment of XXXX : experience of the A Coru  a UHC (Spain)].

answer: @entity2


abstract: Experiments were designed to test, using 76 @entity1 , 1) whether a humoral factor inducing @entity0 is released after partial enterectomy or not, and 2) whether visceral sensitivity conducted to the central nervous system by the route of the vagus plays a role in the @entity0 or not. Vascular parabiosis was established between @entity1 paired for an identical blood group and histocompatibility. A continuous blood cross circulation was maintained for 410 h either between two normal @entity1 or between a normal and a jejunectomized (30 per cent) @entity1 . Their growth and food intake, and the tissue weight of their small intestine were checked. Both the jejunectomized @entity1 and their unoperated partners showed a significant @entity0 of the small intestine, whether residual or intact, as compared to intact @entity1 cross circulated between them. The @entity0 observed in the unoperated partners of the jejunectomized @entity1 was not the result of any @entity3 . There was thus a true humoral mediation of the @entity0 . Vagal deafferentation, i.e. a selective surgical suppression of the vagal afferent (sensory) pathways originating below the diaphragm, was performed in jejunectomized @entity1 . Their performances and small intestine morphology (whole tissue weight and dry weight of the mucosa) were compared to those measured in jejunectomized but vagally intact @entity1 . The dry weight of the mucosa of the residual small intestine in resected @entity1 was restored (after 28 days) at a value similar to that measured for the intact small intestine in controls. Opposite to that, the dry weight of the mucosa of the residual intestine of resected + deafferented @entity1 was significantly lower, due to the absence of any @entity0 . This difference did not result from any change in the food intake level. Therefore it was concluded that vagal afferences from the digestive tract are necessary in eliciting the @entity0 . From these results and some recent bibliographical data, it is tentatively concluded that @entity0 of the residual small intestine after partial enterectomy might be mediated through a neuro-humoral feedback whose afferent way would be the vagal sensory pathway, and efferent way would be a hormonal one monitored by the hypothalamo-hypophyseal @entity2 .

title: XXXX of the residual small intestine after partial enterectomy. A neurohumoral feedback?

answer: @entity0


abstract: BACKGROUND: The neosquamous mucosa that replaces ablated esophageal endothelium after @entity2 for @entity4 or @entity7 ( @entity7 ) may retain buried glandular tissue. This study aimed to assess the @entity1 potential, cellular proliferation, and resistance to apoptosis of this buried glandular tissue by measuring @entity8 , Ki-67, and @entity6 expression in these tissues. METHODS: A prospectively collected database was sourced for esophageal biopsy specimens with normal histologic appearance, @entity4 , @entity7 , @entity5 , and postablation mucosa comprising ablated Barrett's and ablated @entity7 . Quantitative analysis of cellular markers was achieved immunohistochemically using monoclonal antibodies for the @entity8 enzyme (suggesting increased @entity1 potential), Ki-67 antigen (suggesting cellular proliferation), and @entity6 oncoprotein (suggesting oncogenic resistance to apoptosis). Grading was performed by independent, blinded observers, and the pre- and postablation cellular disparities were subsequently noted. RESULTS: The buried glandular elements of postablation mucosa demonstrated universally greater @entity8 , Ki-67, and @entity6 expression than normal esophagus. @entity4 and @entity5 expressed significantly greater @entity8 and Ki-67 at the deep glandular level than postablation mucosa. @entity7 demonstrated greater Ki-67 expression than the postablation tissue but only within the superficial glands. Overall, the expression of @entity8 correlated significantly with Ki-67 expression in deep glandular tissue. CONCLUSIONS: Ablation of pathologic mucosa in @entity4 and @entity7 reduces the expression of some markers of @entity3 . However, the buried glandular tissue of the postablation mucosa still exhibits a higher expression than normal esophageal epithelium. This has potential implications for the follow-up treatment of these @entity0 because it is unclear whether the true risk of @entity1 progression is adequately reduced. A more comprehensive study is required to address this issue.

title: Comparison of @entity8 , Ki-67, and @entity6 expression in normal esophageal mucosa, @entity4 , dysplasia, and XXXX with postablation mucosa and implications for ablative therapies.

answer: @entity5


abstract: BACKGROUND: The neosquamous mucosa that replaces ablated esophageal endothelium after @entity2 for @entity4 or @entity7 ( @entity7 ) may retain buried glandular tissue. This study aimed to assess the @entity1 potential, cellular proliferation, and resistance to apoptosis of this buried glandular tissue by measuring @entity8 , Ki-67, and @entity6 expression in these tissues. METHODS: A prospectively collected database was sourced for esophageal biopsy specimens with normal histologic appearance, @entity4 , @entity7 , @entity5 , and postablation mucosa comprising ablated Barrett's and ablated @entity7 . Quantitative analysis of cellular markers was achieved immunohistochemically using monoclonal antibodies for the @entity8 enzyme (suggesting increased @entity1 potential), Ki-67 antigen (suggesting cellular proliferation), and @entity6 oncoprotein (suggesting oncogenic resistance to apoptosis). Grading was performed by independent, blinded observers, and the pre- and postablation cellular disparities were subsequently noted. RESULTS: The buried glandular elements of postablation mucosa demonstrated universally greater @entity8 , Ki-67, and @entity6 expression than normal esophagus. @entity4 and @entity5 expressed significantly greater @entity8 and Ki-67 at the deep glandular level than postablation mucosa. @entity7 demonstrated greater Ki-67 expression than the postablation tissue but only within the superficial glands. Overall, the expression of @entity8 correlated significantly with Ki-67 expression in deep glandular tissue. CONCLUSIONS: Ablation of pathologic mucosa in @entity4 and @entity7 reduces the expression of some markers of @entity3 . However, the buried glandular tissue of the postablation mucosa still exhibits a higher expression than normal esophageal epithelium. This has potential implications for the follow-up treatment of these @entity0 because it is unclear whether the true risk of @entity1 progression is adequately reduced. A more comprehensive study is required to address this issue.

title: Comparison of XXXX , Ki-67, and @entity6 expression in normal esophageal mucosa, @entity4 , dysplasia, and @entity5 with postablation mucosa and implications for ablative therapies.

answer: @entity8


abstract: BACKGROUND: The neosquamous mucosa that replaces ablated esophageal endothelium after @entity2 for @entity4 or @entity7 ( @entity7 ) may retain buried glandular tissue. This study aimed to assess the @entity1 potential, cellular proliferation, and resistance to apoptosis of this buried glandular tissue by measuring @entity8 , Ki-67, and @entity6 expression in these tissues. METHODS: A prospectively collected database was sourced for esophageal biopsy specimens with normal histologic appearance, @entity4 , @entity7 , @entity5 , and postablation mucosa comprising ablated Barrett's and ablated @entity7 . Quantitative analysis of cellular markers was achieved immunohistochemically using monoclonal antibodies for the @entity8 enzyme (suggesting increased @entity1 potential), Ki-67 antigen (suggesting cellular proliferation), and @entity6 oncoprotein (suggesting oncogenic resistance to apoptosis). Grading was performed by independent, blinded observers, and the pre- and postablation cellular disparities were subsequently noted. RESULTS: The buried glandular elements of postablation mucosa demonstrated universally greater @entity8 , Ki-67, and @entity6 expression than normal esophagus. @entity4 and @entity5 expressed significantly greater @entity8 and Ki-67 at the deep glandular level than postablation mucosa. @entity7 demonstrated greater Ki-67 expression than the postablation tissue but only within the superficial glands. Overall, the expression of @entity8 correlated significantly with Ki-67 expression in deep glandular tissue. CONCLUSIONS: Ablation of pathologic mucosa in @entity4 and @entity7 reduces the expression of some markers of @entity3 . However, the buried glandular tissue of the postablation mucosa still exhibits a higher expression than normal esophageal epithelium. This has potential implications for the follow-up treatment of these @entity0 because it is unclear whether the true risk of @entity1 progression is adequately reduced. A more comprehensive study is required to address this issue.

title: Comparison of @entity8 , Ki-67, and @entity6 expression in normal esophageal mucosa, XXXX , dysplasia, and @entity5 with postablation mucosa and implications for ablative therapies.

answer: @entity4


abstract: BACKGROUND: The neosquamous mucosa that replaces ablated esophageal endothelium after @entity2 for @entity4 or @entity7 ( @entity7 ) may retain buried glandular tissue. This study aimed to assess the @entity1 potential, cellular proliferation, and resistance to apoptosis of this buried glandular tissue by measuring @entity8 , Ki-67, and @entity6 expression in these tissues. METHODS: A prospectively collected database was sourced for esophageal biopsy specimens with normal histologic appearance, @entity4 , @entity7 , @entity5 , and postablation mucosa comprising ablated Barrett's and ablated @entity7 . Quantitative analysis of cellular markers was achieved immunohistochemically using monoclonal antibodies for the @entity8 enzyme (suggesting increased @entity1 potential), Ki-67 antigen (suggesting cellular proliferation), and @entity6 oncoprotein (suggesting oncogenic resistance to apoptosis). Grading was performed by independent, blinded observers, and the pre- and postablation cellular disparities were subsequently noted. RESULTS: The buried glandular elements of postablation mucosa demonstrated universally greater @entity8 , Ki-67, and @entity6 expression than normal esophagus. @entity4 and @entity5 expressed significantly greater @entity8 and Ki-67 at the deep glandular level than postablation mucosa. @entity7 demonstrated greater Ki-67 expression than the postablation tissue but only within the superficial glands. Overall, the expression of @entity8 correlated significantly with Ki-67 expression in deep glandular tissue. CONCLUSIONS: Ablation of pathologic mucosa in @entity4 and @entity7 reduces the expression of some markers of @entity3 . However, the buried glandular tissue of the postablation mucosa still exhibits a higher expression than normal esophageal epithelium. This has potential implications for the follow-up treatment of these @entity0 because it is unclear whether the true risk of @entity1 progression is adequately reduced. A more comprehensive study is required to address this issue.

title: Comparison of @entity8 , Ki-67, and XXXX expression in normal esophageal mucosa, @entity4 , dysplasia, and @entity5 with postablation mucosa and implications for ablative therapies.

answer: @entity6


abstract: The level, distribution, compositional pattern, and possible sources of @entity1 ( @entity2 ) in agricultural soil of Shanghai were investigated. The concentrations ranged from 140.7 to 2,370.8  g kg(   -1) for 21 @entity2 and from 92.2 to 2,062.7  g kg(   -1) for 16 priority @entity2 , respectively. The higher level of @entity2 was mainly distributed in the south and west of Shanghai region, and the lower concentration was found in Chongming Island. Generally, the composition pattern of @entity2 was characterized with high molecular weight @entity2 , the seven possible carcinogenic @entity2 accounted for 4.8-50.8% of the total @entity2 , and @entity5 , @entity3 , and @entity4 were the most dominant components in soil samples. The correlation analysis suggested that low molecular weight @entity2 and high molecular weight @entity2 were originated from different sources and further corroborated that total organic @entity0 was a key soil property affecting the fate of persistent organic pollutants in the environment. The isomer ratios and principal component analysis indicated that @entity2 in the investigated areas were derived primarily from combustion of biomass, coal, and petroleum. Compared to the soil quality standards of the Netherlands, all the target @entity2 (except Ant) in most samples exceeded their target values. The Nemerow composite index based on the same soil quality standard showed that 69.4% of the soil samples were heavily polluted. The total BaP(eq) of ten Dutch target @entity2 in 72% soil samples were higher than the reference total carcinogenic potency. Therefore, the agricultural soil in Shanghai is suffering from serious @entity2 contamination.

title: Contamination, source identification, and risk assessment of XXXX in agricultural soil of Shanghai, China.

answer: @entity1